CAR-T CELL THERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A LARGE OVARIAN EXTRAMEDULLARY MASS
INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood, arising from the bone marrow. ALL may present at diagnosis or relapse at extramedullary sites. In recent years, autologous T-cells engineered to express a chimeric-antigen receptor (CAR-T cells) have emerged as novel immune-based therapies for relapsed and refractory ALL, targeting the B-cell surface antigen CD19. Here we present a patient with relapsed ALL involving the ovaries, treated with CD19 CAR-T cells. Toxicity included cytokine-release syndrome and neurotoxicity. CAR-T cell therapy led to a complete remission, with evidence of CAR-T cell trafficking to disease sites including the bone marrow and ovaries.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:162 |
|---|---|
| Enthalten in: |
Harefuah - 162(2023), 1 vom: 30. Jan., Seite 15-18 |
| Sprache: |
Hebräisch |
|---|
| Beteiligte Personen: |
Jacoby, Elad [VerfasserIn] |
|---|
| Themen: |
Antigens, CD19 |
|---|
| Anmerkungen: |
Date Completed 02.02.2023 Date Revised 02.02.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM352253460 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352253460 | ||
| 003 | DE-627 | ||
| 005 | 20231226053308.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||heb c | ||
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352253460 | ||
| 035 | |a (NLM)36714936 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a heb | ||
| 100 | 1 | |a Jacoby, Elad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CAR-T CELL THERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A LARGE OVARIAN EXTRAMEDULLARY MASS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2023 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood, arising from the bone marrow. ALL may present at diagnosis or relapse at extramedullary sites. In recent years, autologous T-cells engineered to express a chimeric-antigen receptor (CAR-T cells) have emerged as novel immune-based therapies for relapsed and refractory ALL, targeting the B-cell surface antigen CD19. Here we present a patient with relapsed ALL involving the ovaries, treated with CD19 CAR-T cells. Toxicity included cytokine-release syndrome and neurotoxicity. CAR-T cell therapy led to a complete remission, with evidence of CAR-T cell trafficking to disease sites including the bone marrow and ovaries | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antigens, CD19 |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Toren, Amos |e verfasserin |4 aut | |
| 700 | 1 | |a Gefen, Roni |e verfasserin |4 aut | |
| 700 | 1 | |a Shapira, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Arad-Cohen, Nira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Harefuah |d 1946 |g 162(2023), 1 vom: 30. Jan., Seite 15-18 |w (DE-627)NLM000070491 |x 0017-7768 |7 nnns |
| 773 | 1 | 8 | |g volume:162 |g year:2023 |g number:1 |g day:30 |g month:01 |g pages:15-18 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 162 |j 2023 |e 1 |b 30 |c 01 |h 15-18 | ||